Zobrazeno 1 - 10
of 33
pro vyhledávání: '"King Pan Ng"'
Autor:
King Pan Ng, Aditi Manjeri, Lin Ming Lee, Zhu En Chan, Chin Yee Tan, Qiancheng Darren Tan, A'Qilah Majeed, Kian Leong Lee, Charles Chuah, Toshio Suda, S Tiong Ong
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0205254 (2018)
Cancer cells, including in chronic myeloid leukemia (CML), depend on the hypoxic response to persist in hosts and evade therapy. Accordingly, there is significant interest in drugging cancer-specific hypoxic responses. However, a major challenge in l
Externí odkaz:
https://doaj.org/article/05aac69187304e089d4f5ac477267de7
Autor:
Lip Kun Tan, Wing Leung, Teck Guan Soh, Liang Piu Koh, Marieta Chan, Jiashen Loh, Yeh Ching Linn, Michelle Poon, Wee Joo Chng, Thuan Tong Tan, King Pan Ng, Jenny G. Low, Michaela Su-fern Seng, Chik Hong Kuick
Publikováno v:
Advances in Cell and Gene Therapy
ADVANCES IN CELL AND GENE THERAPY
ADVANCES IN CELL AND GENE THERAPY
Objectives To determine whether the frequencies of SARS‐CoV‐2‐specific T cells are sufficiently high in the blood of convalescent donors and whether it is technically feasible to manufacture clinical‐grade products overnight for T‐cell ther
Autor:
Wing Leung, Michaela Su-fern Seng, Lip Kun Tan, Teck Guan Soh, Thuan Tong Tan, Jenny G. Low, Liang Piu Koh, Chik Hong Kuick, Jiashen Loh, Michelle Poon, Marieta Chan, King Pan Ng, Wee Joo Chng, Yeh Ching Linn
SUMMARYBackgroundAdoptive therapy with SARS-CoV-2 specific T cells for COVID-19 has not been reported. The feasibility of rapid clinical-grade manufacturing of virus-specific T cells from convalescent donors has not been demonstrated for this or prio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b59cffb0a2fedc39398ce4b5fa9be9c
https://doi.org/10.1101/2020.04.24.20077487
https://doi.org/10.1101/2020.04.24.20077487
Autor:
Chin Thing J Ong, Qiangze Hoi, Alexis Jiaying Khng, Naoto Takahashi, Zhu En Chan, Audrey S.M. Teo, Axel M. Hillmer, David A. Fruman, Charles Chuah, Wei Jia W Soon, Patrick Tan, Wee Joo Chng, Simeen Malik, King Pan Ng, Kian Leong Lee, Ravi Bhatia, Pauline C. Ng, Tun Kiat Ko, Cheryl Xueli Chan, Xiu Ting Heng, Kim Jiajing Xie, Joanna H.J. Tan, Thushangi N. Pathiraja, Wee Yang Meah, Sheila Xinxuan Soh, Chiea Chuen Khor, Yee Yen Sia, S. Tiong Ong, Oscar Velazquez Camacho, Asif Javed, Xingliang Liu
Publikováno v:
Blood. 135(26)
Targeted therapies against the BCR-ABL1 kinase have revolutionized treatment of chronic phase (CP) chronic myeloid leukemia (CML). In contrast, management of blast crisis (BC) CML remains challenging because BC cells acquire complex molecular alterat
Publikováno v:
Current Molecular Biology Reports. 2:158-170
Xenografting involves the transplantation of human tissue or cells into animal models and is an important tool for regenerative medicine research. Implantation of engineered human bone tissues into animal models, for example, is performed in preclini
Publikováno v:
Transcription. 7:141-151
The multi-functional TET (TAF15/EWS/TLS) or FET (FUS/EWS/TLS) protein family of higher organisms harbor a transcriptional-activation domain (EAD) and an RNA-binding domain (RBD). The transcriptional activation function is, however, only revealed in o
Autor:
Qiancheng Darren Tan, Toshio Suda, King Pan Ng, Aditi Manjeri, Charles Chuah, S. Tiong Ong, Chin Yee Tan, A'Qilah Majeed, Lin Ming Lee, Kian Leong Lee, Zhu En Chan
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0205254 (2018)
PLoS ONE
PLoS ONE
Cancer cells, including in chronic myeloid leukemia (CML), depend on the hypoxic response to persist in hosts and evade therapy. Accordingly, there is significant interest in drugging cancer-specific hypoxic responses. However, a major challenge in l
Publikováno v:
Oncotarget
// Tun Kiat Ko 1 , Charles T.H. Chuah 1,2 , John W.J. Huang 1 , King-Pan Ng 1 and S. Tiong Ong 1,2,3,4 1 Cancer and Stem Cell Biology Program, Duke-NUS Graduate Medical School, Singapore 2 Department of Haematology, Singapore General Hospital, Singap
Autor:
Weijie Huang, Lorenz Poellinger, King Pan Ng, Soo Yong Tan, Kian Leong Lee, Aditi Manjeri, Charles Chuah, S. Tiong Ong
Publikováno v:
Blood
Blood; Vol 123
Blood; Vol 123
C-abl oncogene 1, nonreceptor tyrosine kinase (ABL1) kinase inhibitors such as imatinib mesylate (imatinib) are effective in managing chronic myeloid leukemia (CML) but incapable of eliminating leukemia stem cells (LSCs), suggesting that kinase-indep
Publikováno v:
Biochemistry. 48:2849-2857
Aberrant chromosomal fusion of the Ewings sarcoma oncogene (EWS) to several different cellular partners gives rise to the Ewing's family of oncogenic proteins [EWS fusion proteins (EFPs)] and associated tumors (EFTs). EFPs are potent transcriptional